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Objectives. The purpose of this study was to determine patient
characteristics that are a priori predictors of early infarct related
artery patency following thrombolytic therapy, and to provide a
paradigm which may identify patients who would be most likely to
achieve restoration of normal (TIMI 3) coronary flow in response
to thrombolytic therapy.
Background. Restoration of infarct-related artery perfusion in
acute myocardial infarction is necessary for preservation of
ventricular function and mortality reduction. Clinical variables
that are a priori predictors of early patency with currently
available thrombolytic regimens have not been fully characterized.
Methods. The probability of early infarct-related artery patency
(TIMI 3 flow) was determined by multivariable logistic regression.
We determined a reduced (parsimonious) model for predicting
early (90 min) infarct-related artery patency (TIMI grade 3) based
on data from 1,030 patients in the GUSTO-I Angiographic study.
Results. Predictors of 90 min TIMI 3 flow are use of an
accelerated t-PA regimen (vs. streptokinase containing regimens)
(x2 5 39.1; p <2 0.0001), infarct related artery (RCA/Lcx vs. LAD)
(x2 5 12.7; p 5 0.0004), body weight (x2 5 10.3; p 5 0.001) and
history of smoking (x2 5 7.4; p 5 0.007). Time from symptom
onset to treatment was not significant (p 5 0.71).
Conclusions. The efficacy of currently available thrombolytic
regimens is chiefly dependent on choice of thrombolytic regimen,
body weight, infarct-related coronary artery and smoking history.
Clinical variables alone correctly predict a priori TIMI 3 flow in
the infarct-related artery 64% of the time. Patients with body
weights greater than 85 kg are at a significant disadvantage with
regard to achieving successful thrombolysis compared to those
with lesser body weights.
(J Am Coll Cardiol 1998;32:641–7)
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Mortality reduction in acute myocardial infarction is depen-
dent upon the efficacy of thrombolytic regimens with regard to
reestablishing normal infarct-related artery flow (1). Successful
reperfusion of initially occluded infarct-related coronary arter-
ies is the result of a complex interplay among clinical, hemo-
dynamic, mechanical and biochemical factors (2). Clinical
variables that determine the efficacy of thrombolytic therapy,
however, have been poorly described. The Global Utilization
of Streptokinase and t-PA for Occluded Coronary Arteries
(GUSTO-I) Angiographic Study offered the unique opportu-
nity to determine clinical determinants of early (90 min)
infarct-related artery patency. The purpose of this study is to
describe those patient or treatment variables of greatest im-
portance in determining a priori early infarct-related artery
patency following thrombolytic therapy. We also sought to
develop a predictive model based on clinical variables that
could possibly be used as a paradigm for determining the
likelihood of thrombolytic therapy success.
Methods
Study patients. The GUSTO-I Angiographic study has
been described in detail previously (3). Briefly, patients were
enrolled in GUSTO-I if they experienced chest pain ,6 hs in
duration and had electrocardiographic evidence of acute myo-
cardial infarction (ST segment elevation). Patients were ran-
domized to one of four treatment regimens which included 1)
streptokinase with subcutaneous heparin; 2) streptokinase with
intravenous heparin; 3) accelerated dose t-PA with intravenous
heparin; and 4) combination therapy with t-PA and streptoki-
nase with intravenous heparin. Patients were also randomized
to one of four time periods for angiography (3). This study
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includes coronary angiographic data from those patients ran-
domized to 90 min postthrombolytic therapy angiography with
cine films adequate for determining infarct-related artery flow
grade.
Core angiographic laboratory cineangiographic analysis.
All cine films were interpreted by an experienced angiographer
(CFL, JSR, AMR) who had no knowledge of treatment
allocation or angiographic time randomization as described in
the Thrombolysis in Myocardial Infarction (TIMI) trial (4).
Coronary segments identified as the infarct-related segment
were considered proximal if they occurred prior to or imme-
diately following the first septal perforator in the left anterior
descending coronary artery, prior to the second marginal
branch of the right coronary artery or prior to the second
marginal branch of the left circumflex artery. All other infarct-
related segments were considered distal sites.
Statistical analysis. Exploratory data analyses were per-
formed to determine the relationship between individual clin-
ical variables and patency (TIMI 3 flow) in 1,030 patients
randomized to 90 min angiography with complete data sets.
Analyses of patency determinants were done only for those
patients with native coronary arteries as the infarct-related
vessel. Boxplots and contingency tables were utilized to con-
ceptually compare the distributions of continuous and discrete
variables with respect to patency. The Kolmogorov-Smirnov
test was used to compare the empirical distribution of contin-
uous variables (5). ANOVA and the median test were used to
compare the means and medians of continuous variables
respectively (5). Contingency tables and the Fisher’s exact test
were used to compare categorical data (5). Single variable and
multivariable logistic regression models were developed to
determine which clinical variables were predictors of 90 min
postthrombolytic therapy patency (6). Both ordinal (propor-
tional odds model) and binary outcomes were considered. The
goal of multivariable modelling was to create a final reduced
(parsimonious) model that would predict early patency as well
as a full model. The c-index was used to quantify the predictive
discrimination of a specific model (7). The c-index is equivalent
to the area under the receiver operating characteristic curve. A
c-index of 0.5 would indicate that a given model predicted
patency no better than a coin flip (8). The relative weight of
each independent variable in the final reduced model was
determined by comparison of the standardized estimate coef-
ficient of each variable (9). The full model contained all
possible predictors of infarct-related artery patency, including
appropriate interaction terms. These variables were chosen
based on their contribution to 30-day postinfarction mortality
as described by Lee et al. and based on data from the 41,021
patient GUSTO-I trial (7). They included age, gender, diabe-
tes, history of hypertension, smoking status (never smoked,
current smoker, history of smoking), time from symptom onset
to treatment, height (cm), body weight (kg), infarct sight
(anterior, other), history of hypercholesterolemia, history of
coronary artery bypass surgery, history of previous myocardial
infarction, history of angina, study entry pulse, systolic and
diastolic blood pressure, study entry Killip class, and age and
Killip class interaction, treatment regimen and body weight
interaction. Killip class at study entry was dropped from the
final model due to the extreme skewness of the distribution of
this data set with only 1% of patients entered into the study
being classified as Killip class III or IV. We did not examine
ECG related variables, such as ST segment changes, because
the purpose of this study was to identify patient-related
variables that may identify a priori (that is, prior to thrombo-
lytic drug administration) the likelihood of successful throm-
bolysis. Unadjusted and adjusted odds ratios for 90-min pa-
tency (TIMI 3 flow) were determined from single and
multivariable logistic regression models.
Results
Univariate analysis. The GUSTO-I Angiographic Study
enrolled 1,077 patients who were randomized to 90-min post-
thrombolytic therapy angiography who had adequate coronary
angiographic images for determination of TIMI flow grade.
Tables 1 and 2 display 90-min infarct related artery patency
status according to various patient characteristics and treat-
ment regimens. Patients who achieved normal (TIMI 3) coro-
nary flow 90 min posttherapy were more likely to have the right
or left circumflex coronary artery as the infarct related vessel
(Table 1A). As shown in Table 1B, 90-min TIMI 3 flow was
noted in greater proportion of those patients with either
proximal right coronary artery or proximal left circumflex
coronary artery as the presumed site of the culprit lesion
compared to angiographically determined distal locations of
either of these vessels or a proximal left anterior descending
coronary artery location. Patients with early TIMI 3 flow had









n (%) p Value
LAD 130 (31.3) 151 (36.4) 134 (32.3) 0.001*
RCA 197 (40.8) 127 (26.3) 159 (33.0)
LCx 58 (44.0) 27 (20.4) 47 (35.6)
SVG 7 (28.0) 5 (20.0) 13 (52.0)
LM 1 (17.0) 2 (29.0) 3 (43.0)
Unknown 16 (100)
IRA 5 infarct-related artery. LAD 5 left anterior descending coronary
artery. RCA 5 right coronary artery. LCx 5 left circumflex coronary artery.
SVG 5 Saphenous vein graft. LM 5 left main coronary artery. * 5 p Value for
comparison of TIMI 3 vs. TIMI 0,1,2 flow in LAD vs. RCA 1 LCx.
B. Proximal Distal p Value
LAD 124/395 (31%) 6/20 (30%) 0.002*
LCx 56/122 (50%) 2/10 (20%) 0.038†
RCA 160/375 (43%) 37/108 (34%) 0.008‡
Values represent proportion of infarct-related artery location with 90 min
post thrombolytic therapy TIMI 3 flow. * 5 p Value for comparison of proximal
LAD vs all other categories. † 5 p Value for comparison of proximal LCx vs. all
other categories. ‡ 5 p Value for comparison of proximal RCA vs. all other
categories.
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significantly lower body weights and were more likely to have
a history of smoking compared with those patients with less
than normal flow. Patients with 90-min TIMI 3 flow were also
more likely to have received the accelerated t-PA regimen
rather than a streptokinase regimen. Of note, the distribution
of time from symptom onset to treatment were similar in
patients who achieved normal coronary flow and those with
less than normal flow. Univariate analysis failed to detect any
difference in those patients with TIMI 3 flow compared to
those with less than TIMI 3 flow with regard to age, gender or
traditional cardiovascular risk factors such as diabetes, hyper-
tension or lipid status. Hemodynamic parameters at the time
of study entry such as heart rate, systolic or diastolic blood
pressure were not clinically different between these two
groups.
Multivariable analysis. Predictors of 90-min TIMI 3 flow
are shown in Table 3. Use of an accelerated t-PA regimen,
infarct related artery (right and circumflex coronary artery vs
left anterior descending coronary artery), body weight and
history of smoking were each significant determinants of
90-min infarct-related artery flow status. The relative weight of
each of these variables with regards their contribution to the
probability of 90-min TIMI 3 flow is 2.2:1.3:1.2:1.0, respec-
tively. Substitution of infarct related artery specific segment of
presumed occlusion (i.e., proximal vs. distal) for infarct-related
artery as a candidate variable for testing by multivariable
analysis resulted in the inclusion of proximal right and left
circumflex infarction related coronary segments (vs. all other
sites) in the model (x2 5 16.0; p 5 0.0001). Time from
symptom onset to treatment was not significant as a predictor
of early TIMI 3 flow (x2 5 0.13; p 5 0.71). Time to treatment
was only of marginal significance (p 5 0.03) when patency
outcome was analyzed as a dichotomous variable (TIMI 2,3 vs
TIMI 0,1) (odds ratio 0.89; 95% confidence limits 0.80–0.99);
Of note, age (p 5 0.08), gender (p 5 0.16), diabetes (p 5 0.08),
and hypercholesterolemia (p 5 0.46) were not significant
predictors of 90-min infarct-related artery TIMI 3 flow. The
c-index for this model is 0.64. This reduced model contains
.90% of the information found in a model containing all
tested clinical variables.
Figure 1 displays the probability of 90-min TIMI 3 flow as
a function of body weight adjusted for treatment regimen and
infarct related artery in patients who never smoked. There is a
1.6 fold (95% confidence limits 1.2–2.1) greater likelihood of
achieving 90-min posttherapy TIMI 3 flow if the infarct-related
artery is either the right or circumflex coronary vessel com-
pared with the left anterior descending coronary artery regard-
less of the treatment regimen. This effect is relatively constant
over the range of patient body weights included in this study.
Figure 2 shows there is a 2.5 times greater likelihood of
achieving 90-min TIMI 3 flow with the use of an accelerated
Table 2. Patient Characteristics According to 90 Minute TIMI Flow
Grade (n 5 1030)
A. TIMI 3
Continuous Variables
p Value*TIMI 2 TIMI 0,1
Age (yrs) 60 (50, 69) 62 (52, 70) 61 (52, 69) 0.100
Weight (kg) 75 (67, 86) 77 (68, 86) 80 (70, 90) 0.004
Height (cm) 171 (165, 178) 171 (165, 178) 173 (167, 178) 0.289
Time to Rx
(all Rxs’)
2.8 (2,0, 3.7) 2.8 (2.0, 3.8) 3.0 (2.1, 4.2) 0.097
Time to Rx
(t-PA)
2.8 (1.9, 3.5) 3.1 (2.5, 4.3) 2.6 (1.9, 3.7) 0.224
Time to Rx
(SK, IV)
2.8 (1.9, 3.6) 2.8 (2.1, 3.8) 3.2 (2.1, 4.4) 0.210
Time to Rx
(SK, SQ)
2.5 (1.9, 3.8) 2.5 (1.8, 3.5) 2.9 (2.1, 3.9) 0.213
Time to Rx
(t-PA 1 SK)
2.8 (2.1, 4.0) 2.6 (1.9, 3.6) 3.2 (2.3, 4.5) 0.900
Heart Rate 71 (61, 84) 74 (63, 85) 73 (64, 85) 0.068
Systolic blood
pressure
128 (110, 142) 130 (115, 146) 127 (112, 145) 0.264
Diastolic blood
pressure
80 (67, 90) 80 (70, 90) 80 (70, 90) 0.018
Values represent median (25th, 75th percentiles). * 5 p value for compar-
ison of medians for TIMI 3 flow vs. combined TIMI 0,1,2 flow.
B. TIMI 3 TIMI 2 TIMI 0,1 p Value
Gender
Male 76.2 76.1 79.1 0.723
Diabetes 14.5 13.8 12.1 0.461
Hx Htn 37.0 39.0 35.1 0.996
Hyperchol. 33.4 30.2 34.0 0.666
Smoking
History 70.0 59.0 62.1 0.004
Current 48.0 44.0 47.3 0.437
Hx angina 35.1 32.0 30.0 0.195
Hx AMI 12.2 13.0 11.2 0.912
Hx CABG 2.3 1.0 1.5 0.184
Killip class
I 86.0 91.0 88.0 0.392
II 13.0 9.0 10.0
III 1.0 0.3 1.8
IV 0.3 0.0 0.6
Rx regimen
t-PA 36.5 23.3 14.4 0.001*
SK(IV 1 SQ) 36.8 45.2 64.1
t-PA 1 SK 26.7 31.5 21.5
Values represent proportion of patients in each category. Htn 5 hyperten-
sion. Smoking history 5 current plus past smokers. * 5 p value for comparison
of patients receiving t-PA with resultant TIMI 3 flow vs. patients receiving all
other treatment regimens.
Table 3. Multivariable Analysis: Predictors of 90 Minute Infarct-
Related Artery (IRA) TIMI 3 Flow
Variable
Parameter
Estimate Wald x2 p Value
t-PA 0.91 39.1 0.0001
IRA 20.49 12.7 0.0004
Weight (kg) 20.02 10.3 0.0013
Hx Smoking 0.38 7.35 0.0070
Parameter estimate for IRA refers to left anterior descending coronary
artery vs. combination of left circumflex and right coronary arteries. Parameter
estimate for body weight is for any one kilogram difference in weight.
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t-PA regimen compared with streptokinase regimens. This
effect is also constant over the range of patient body weights
and infarct-related arteries. Figure 2 also displays the adjusted
odds ratios for 90-min TIMI 3 flow according to infarct related
artery, patient smoking history and a range of body weights.
The body weights chosen represent the 10%, 50%, 75%, 90%
and 95% percentiles of patient body weights in this study. For
any 1 kg difference in body weight, the odds ratio for achieving
90-min TIMI 3 flow is 1.02 with the greater likelihood in favor
of the lower body weight. For any 17, 28, 38, or 43 kg difference
in body weight, the respective odds ratios are 1.3, 1.6, 1.9 and
2.0, respectively, in favor of the lower body weight.
Discussion
The GUSTO-I trial and GUSTO-I Angiographic Study
provided powerful evidence supporting the hypothesis that
infarct-related artery patency is of prime importance with
regards to preservation of left ventricular function and mor-
tality reduction in the setting of acute myocardial infarction
(1,3,10). The GUSTO-I Angiographic Study, due to its large
size, also provided for the first time a unique opportunity to
examine the primary clinical predictors of early (90 min) and
normal (TIMI 3) reperfusion following thrombolytic therapy.
The primary predictors of 90-min infarct-related artery pa-
tency are: 1) use of an accelerated t-PA regimen; 2) body
weight; 3) the infarct-related artery; and 4) a history of
smoking.
Patency, thrombolytic therapy regimen and body weight. A
substantial reduction in the likelihood of achieving TIMI 3
flow occurs for successive increments in body weight when
t-PA is the thrombolytic agent of choice and delivered in an
accelerated manner as described by Neuhaus et al. (11). In
patients weighing $85 kg, the probability of achieving TIMI 3
flow in an occluded left anterior descending coronary artery is
less than 50% (47% in patients with a history of smoking; 38%
in those who never smoked) using the t-PA regimen described
in GUSTO-I. For patients weighing $105 kilograms the prob-
ability of 90-min TIMI 3 flow with t-PA falls to 39% in those
with a smoking history and 30% in those patients who never
smoked. Of note, 23% of the patients enrolled in the
GUSTO-I Angiographic Study had body weights greater than
85 kg. These data are very similar to the TEAM-3 results of
24-h infarct-related artery patency using t-PA delivered over
3 h (12). Use of a streptokinase regimen resulted in even
greater reduction in the likelihood of early patency between
the lowest body weight quantile and the highest quantile.
Streptokinase containing regimens are associated with a 45%–
48% reduced likelihood of TIMI 3 flow 90 min postthrombo-
lytic therapy over the entire range of patient body weights
examined compared with the accelerated t-PA regimen in
those patients with acute anterior myocardial infarctions.
These data suggest that the current dosage recommenda-
tions for t-PA and streptokinase may be less than optimal for
achieving a maximal effect on early patency in patients weigh-
ing more than 80–85 kg.
Patency and infarct-related artery. There are conflicting
reports concerning the effect of infarct related artery location
on early patency in response to thrombolytic therapy. The
TIMI I investigators reported a greater reperfusion rate (TIMI
2 1 TIMI 3) in the left anterior descending coronary artery
compared to either the right or circumflex coronaries in
patients who received double chain t-PA (4). They were unable
to detect an effect on infarct segment location (proximal vs.
distal) on the likelihood of reperfusion (4). The TAMI I
investigators reported a statistically insignificant trend toward
a higher patency rate (TIMI 2 plus TIMI 3) 90 min after
initiation of thrombolytic therapy with t-PA when the left
anterior descending coronary artery was the infarct-related
artery (13). They reported an insignificant trend toward less
successful reperfusion with proximal infarct related segments
Figure 1. Logistic regression analysis. The probability of 90 min
infarct-related artery TIMI 3 flow adjusted for body weight and infarct
artery in patients who never smoked. } 5 t-PA, right or circumflex
coronary artery.  5 t-PA, left anterior descending coronary artery.
{ 5 streptokinase regimen, right or circumflex coronary artery. D 5
streptokinase regimen, left anterior descending coronary artery.
Figure 2. Multivariable analysis: adjusted odds ratios with 95% con-
fidence limits for infarct related artery TIMI 3 flow 90 min postthrom-
bolytic therapy according to treatment regimen, infarct related artery
and body weight. The 95% confidence limits for any given weight
difference displayed are small and contained within the diamond
representation. A ratio .1.0 denotes greater likelihood TIMI 3 flow
relative to TIMI 0,1 or 2 flow. SK 5 streptokinase. IRA 5
infarct-related artery. RCA/Lcx 5 right coronary artery and left
circumflex coronary artery. LAD 5 Left anterior descending coro-
nary artery.
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compared with distal segments (13). Multivariable modeling
for patency determinants was not done in either the TIMI I nor
TAMI I studies (4,13). Anderson et al., reporting for the
TEAM-2 Investigators, found a significantly greater reperfu-
sion rate (TIMI 2 1 TIMI 3) in the combined right and
circumflex coronary arteries compared to the left anterior
descending with anistreplase but no difference in vessel-
specific patency rates with streptokinase (14). Pacouret et al.
and Leizorovicz et al. failed to find any significance of infarct-
related artery on patency (TIMI 2 1 TIMI 3) rates with either
anistreplase or streptokinase even after adjustment for clinical
variables (15,16). Our database represents the largest single
trial patient population with complete demographic and an-
giographic data sets thus far utilized to detail important
predictors of early infarct-related artery patency. It appears by
multivariable analysis that the likelihood of achieving TIMI 3
flow 90-min postthrombolytic therapy in the right or left
circumflex coronary artery is approximately 1.3 to 2.1 fold
greater than the likelihood of achieving normal reperfusion in
the left anterior descending coronary vessel. The location of
the infarct segment within the infarct-related artery, that is,
proximal or distal, also appears to be of importance and retains
significance following adjustment for multiple clinical vari-
ables. The reason for the greater likelihood of achieving early
normal flow in the right or circumflex vessels and in more
proximal infarct segments of these vessels is most likely
multifactorial and related, for example, to thrombus burden
(2,4), plaque burden and possibly collateral flow in the infarct
region (17). We are unable to determine the effect of collateral
flow on early postthrombolytic therapy infarct-related artery
patency because our database does not include pretreatment
assessment of collateral flow status.
Patency and smoking. A detailed analysis of the paradox-
ical beneficial effects of smoking with regard to mortality in
patients receiving thrombolytic therapy for acute myocardial
infarction has been reported using the GUSTO-I Angiographic
Study database (18). A significant difference was noted in early
(90-min) TIMI 3 patency rates between patients with a history
of smoking and those who never smoked in favor of those with
a smoking history (41% vs. 33%, p 5 0.02). The TEAM-2
investigators also reported that current smokers have a signif-
icantly greater chance of achieving TIMI 3 flow in infarct
related arteries 90–240 min following thrombolysis in patients
treated with either streptokinase or anistreplase (19). The
beneficial effect of smoking remained significant in that study
after adjustment for baseline clinical and angiographic vari-
ables and was independent of the infarct-related artery (19).
Our current analysis, based on a much larger data set, supports
the TEAM-2 findings with regard to early patency and patient
smoking status. The physiologic mechanism responsible for
this phenomena remains to be explained but may be related to
a greater initial thrombus burden and less plaque burden in
smokers (18).
Patency and time to treatment. Of note, time to treatment
was not an important predictor of the likelihood of successful
(TIMI 3) infarct-related artery reperfusion following adjust-
ment for multiple clinical variables. The likelihood of success-
ful reperfusion has been noted to decline with increasing times
from symptom onset to thrombolytic therapy with streptoki-
nase and anistreplase in several previous studies (4,16,20–22).
Recently, the RAPID II investigators, upon univariate sub-
group analysis, reported a significant effect of time to treat-
ment on the occurrence of TIMI 3 flow in the infarct-related
artery with both double bolus reteplase and an “accelerated”
infusion of t-PA (23). The TIMI I investigators, in a much
smaller sample size compared to GUSTO-I, reported that
streptokinase exhibited diminished efficacy with regard to
reperfusion, measured as TIMI 2 or TIMI 3 flow, in the
infarct-related artery in patients treated between 4–6 h after
symptom onset compared to those treated within 4 h (44% vs
27%) (4). They noted no such time dependent difference with
regard to patency when t-PA was used as the thrombolytic
agent (4). The TIMI I (4) investigators did not report separate
90 min postthrombolysis TIMI 2 and TIMI 3 patency rates for
comparison with our data. However, it is of interest that repeat
analysis of our data using the endpoint of 90 min postthrom-
bolysis patency defined as a dichotomous variable (TIMI 2,3 vs
TIMI 0,1) did demonstrate that time from symptom onset to
treatment was of marginal significance with regard to patency
(p 5 0.03). Time to treatment may assume more importance
with regard to the likelihood of achieving either TIMI 2 or 3
infarct-related artery flow when time from symptom onset to
treatment exceeds 6 h as was the case in TIMI I (4) and
RAPID II (23). However, we are unable to address this issue
with our database as GUSTO-I limited enrollment to those
patients with symptom onset #6 h prior to treatment. It is
generally recognized that TIMI 2 flow represents an inade-
quate degree of reperfusion postthrombolysis (1,24). However,
a significant proportion of patients with TIMI 2 flow 90 min
postthrombolytic therapy develop TIMI 3 flow in the infarct-
related vessel during the first week postinfarction and subse-
quently demonstrate improvement in systolic ventricular func-
tion (25). Therefore, shorter times to treatment, within a 6-h
window, may be of some benefit, although probably marginal,
with regard to restoration of infarct-artery patency. However,
time to treatment should not be considered of special impor-
tance with regard to the likelihood of achieving fully normal
(TIMI 3) reperfusion postthrombolysis if thrombolysis is at-
tempted within 6 h of symptom onset.
Implications of results. The quest for greater reperfusion
success with alternative dosing regimens of existing and inves-
tigational thrombolytic agents must be balanced against the
risks of increasing the incidence of stroke or cerebral hemor-
rhage. Although the use of an accelerated dosing regimen of
t-PA is associated with an increased risk of stroke (relative to
streptokinase) (10), detailed data regarding the dose/unit body
weight/infusion rate vs. stroke are not available. Based on
aggregate data from several small studies it would appear that
early infarct-related artery patency is dependent on the rate of
infusion of t-PA, whereas the likelihood of intracranial hem-
orrhage is more related to total thrombolytic dose and the level
of concomitant anticoagulation (26,27). On the basis of the
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present study observations it would seem clear that further
investigation is needed regarding alternative lytic dosing in
patients with body weights greater than 85 kg using the
thrombolytic agents described in this study.
Study limitations. The principle limitation of this study is
the sensitivity and specificity of our multivariable model for
determining the probability of 90-min postthrombolysis
infarct-related artery patency. As noted above, the predictive
discrimination of this model is not especially strong (c index 5
0.64). The false positive rate and false negative rate to be
expected with this model are 40% and 33%, respectively. This
suggests that this model should not be used as a clinical tool to
predict early successful reperfusion following thrombolytic
therapy (28). Rather this model should be considered descrip-
tive with regard to the main clinical predictors of early
infarct-related artery patency and suggests problem areas that
need to be addressed in designing future treatment strategies.
It should be noted that the odds ratios and relative weights that
each variable in the model contributes to the final prediction of
infarct-related artery patency is dependent on the adequacy
and completeness of the independent variables tested. A
model with improved predictive discrimination with regard to
early patency would probably need to include incompletely
understood hematologic and metabolic variables related to
patency but which were not available for incorporation into our
model.
A second limitation is the subjective nature of quantifying
the primary outcome variable of this study, i.e., patency. A
change in classification of infarct-related artery status from
TIMI 3 to TIMI 2 or vice versa could potentially alter the
results of our multivariable model. However, repeating our
analysis using an outcome variable of TIMI 2 1 TIMI 3 flow
failed to show marked differences from the results described
above. In addition, there were no major differences between a
proportional odds model and the logistic regression model
presented above using a binary outcome. These results suggest
that the degree of “misclassification” of either TIMI 2 or TIMI
3 flow did not contribute significantly to our findings.
Conclusions. The primary predictors of early infarct artery
patency (TIMI 3 flow) are the use of an accelerated t-PA drug
regimen, body weight, the particular infarct-related artery and
patient smoking history. Our data suggests that nonsmoking
patients with anterior infarctions and body weights greater
than 85 kg are at a significant disadvantage with regard to
achieving early successful reperfusion. Alternative strategies,
including either augmented thrombolytic dose regimens or
mechanical reperfusion methods, should be carefully consid-
ered in such patients.
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